Clinical Trial

Treatment of Spinal Cord Injury Using Autologous Concentrated Growth Factors

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
Spinal cord injury (SCI) is a severe disorder of the central nervous system, and effective clinical management remains a significant global challenge. Current therapeutic approaches can only partially restore neurological function, leaving the majority of individuals with SCI facing profound and lifelong disabilities. The Department of Spine Surgery at the Third Affiliated Hospital of Sun Yat-sen University is conducting a clinical study on the use of autologous concentrated growth factors for the treatment of spinal cord injury, with the aim of developing a novel and effective clinical intervention strategy.
Trial Details
NCT Number NCT07253233
Lead Sponsor Third Affiliated Hospital, Sun Yat-Sen University
Conditions Spinal Cord Injury
Enrollment 10 participants
Start Date 2025-12-01
Primary Completion 2027-07-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-28